Loading viewer...
investor_presentation
Format: PDF investor_presentation
ISS presents Q1 2024 trading update with organic growth driven by price and volume expansion, completed DKK 209m share buyback, and confirmed 2024 outlook. Commercial segment shows solid development with strong customer retention, while M&A activities include France divestment completion and gammaRenax acquisition in Switzerland.
investor_presentation
24 Pages
Zentalis Pharmaceuticals Investor Presentation — June 2022
investor_presentationinvestor_presentation
56 Pages
Zentalis Pharmaceuticals, Inc.
TAAL Blockchain Processing Platform Investor Presentation 2021
investor_presentationinvestor_presentation
18 Pages
TAAL Distributed Information Technologies